This analysis reports on the potential of albumin and novel biomarkers in assessing risks in liver cirrhosis, suggesting proteomics can enhance disease management.
Liver cirrhosis is a major global health concern, often progressing to ascites, which worsens prognosis and increases healthcare costs. Current diagnostic approaches rely on albumin-based markers like the serum-ascites albumin gradient, but these have limitations. Emerging biomarkers such as kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin show promise in identifying acute kidney injury in cirrhotic patients. Integrating multi-omics approaches may improve early detection and management of cirrhosis-related complications. Using kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin alongside traditional markers could enhance risk stratification and patient outcomes.
No takes yet. Share an insight, caveat, or question.
Momoh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: